Tracy Evans, MD

Dr. Tracy Evans is a board-certified dermatologist, a skin cancer specialist, a fellowship-trained Mohs surgeon and a trusted provider of cosmetic procedures. She works diligently to balance the important connection between the medical and aesthetic qualities of skin. By using holistic approaches when possible and focusing on overall health and wellness, Dr. Evans helps her patients achieve radiant, glowing skin that bring out their confidence. Dr. Evans graduated with honors, Phi Beta Kappa, from Vassar College in New York. She earned her master’s degree in public health and medical degree from University of Connecticut. She then went on to conduct skin cancer research for the National Institute of Health for two years. Dr. Evans completed her dermatology residency at Emory University in Atlanta, GA and was fellowship trained and certified by the American College of Mohs Micrographic Surgery and the Accreditation Council of Graduate Medical Education at the University of Pittsburgh Medical Center. In addition to her practices in San Francisco and Corte Madera, she has presented at multiple national and international meetings for her research on cost, quality of life, and skin cancer outcomes.

Dr. Evans is dedicated to providing her patients with skin care treatments and services that always exceed their expectations. Whether patients are seeking medical treatment for skin cancer or other skin conditions or cosmetic services to rejuvenate their appearance, they can feel confident about Dr. Evans's skills and expertise. She sees her patients at her two California practices, Pacific Skin and Cosmetic Dermatology San Francisco & Marin and Pacific Skin and Cosmetic Dermatology Corte Madera, for services ranging from Mohs surgery and laser therapy for skin cancer to BOTOX, facials, and nonsurgical skin tightening. Dr. Evans has also developed a proprietary treatment plan for patients who suffer from melasma.

Dr. Evans is an active member of the following societies:

• Fellow of the American Academy of Dermatology
• The American Society of Dermatologic Surgery
• The American Society for Laser Medicine and Surgery
• The American College of Mohs Surgery
• The California Society for Dermatology and Dermatologic Surgery
• The American Medical Association

• California
• Arizona
• Pennsylvania
• Georgia

Private Practice: Surgical, Medical, and Cosmetic Dermatology
Fellowship-trained Mohs Surgeon and Skin Cancer Specialist

2008 – Present

Post Doctoral Training

Associate of American College of Mohs Surgery

2009

Board-Certified Dermatologist
August 11, 2008

ACMMSCO/ACGME Mohs & Procedural Dermatology Fellowship
Fellowship Directors: John A. Zitelli, MD and David G. Brodland, MD

• Cutaneous Oncology: 2,500 cases/year, fellow performs 1,000 cases, including: BCC, SCC, Merkel Cell, AFX, DFSP, extramammary Paget's disease, sebaceous carcinoma, Lentigo Maligna, Melanoma with MART-1 immunoperoxidase stains for margin control
• Reconstruction & Cosmetics: flaps, full and split thickness skin grafts, cartilage grafting, ear reconstruction, scar revision, BOTOX, lasers, sclerotherapy

2007 – 2008

Dermatology Chief Resident Emory University School of Medicine, Department of Dermatology
Chairman: S. Wright Caughman, MD

2006 – 2007

Dermatology Resident Emory University School of Medicine, Department of Dermatology
Chairman: S. Wright Caughman, MD

2004 – 2007

Dermatology Outcomes Research Fellowship
National Research Service Award, National Institute of Health, funded research fellow at Emory University Department of Dermatology and Emory Center for Outcomes Research
Mentor: Suephy C. Chen, MD, MS

2002 – 2004

Transitional Internship Emory University Department of Medicine
Chairman: Wayne Alexander, MD, PdD

2001 – 2002

University of Connecticut School of Medicine Doctor of Medicine

1997 – 2001

University of Connecticut School of Public Health Master of Public Health

1997 – 2001

Master in Public Health Thesis: Evidence-guided approach to understanding the contribution of dietary factors in the prevention and treatment of nonmelanoma skin cancer and melanoma. (Bialy TL, Rothe MJ, Grant-Kels JM. Dietary factors in the prevention and treatment of nonmelanoma skin cancer and melanoma. Dermatologic Surgery, 28:12, 2002, 1143 – 52.)

1999 – 2001

Vassar College Bachelor of Arts
Graduated with honors, Phi Beta Kappa

1990 – 1994

Bramlette TB, Lawson DH, Washington CV, Veladar E, Johns B, Freedman S, Abromova L, Chen SC. 2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon alfa-2b. Dermatologic Surgery, 33 (1) 11 – 16. Winner of 2006 ASDS Young Investigators Writing Competition, July 2006.

Seidler AM, Bramlette TB, Washington CV, Setzo H, Whalen J, Chen SC. Mohs versus traditional surgical excision for facial and auricular nonmelanoma skin cancer: An analysis of cost effectiveness. Dermatologic Surgery, September 2009.

Bialy TL, Whalen J, Veledar E, Chartier T, Lafreniere D, Spiro J, Chen SC. Mohs surgery vs standard excision: A cost comparison analysis. Arch Dermatol, 2004; 140:736 – 742.

Charles CA, Bialy TL, Falabella AF, Eaglstein WH, Kerdel FA, Kirsner RS. Poor prognosis of arthritis-associated pyoderma gangrenosum. Arch Dermatol, 2004; 140(7):861 – 864.

Bialy TL, Rothe MJ, Grant-Kels JM. Dietary factors in the prevention and treatment of nonmelanoma skin cancer and melanoma. Dermatologic Surgery, 2002 Dec; 28(12):1143 – 52.

Rothe MJ, Bialy TL, Grant-Kels JM. Erythroderma. Dermatologic Clinics, Inpatient Dermatology. July 2000, 18; 405 – 415.

Bialy TL, Wei H. Epidermodysplasia verruciformis. In: Lebwohl M, Heymann W, Berth-Jones J, Coulson I, editors. Treatment of Skin Disease, Harcourt Health Sciences, 2002.

Rothe MJ, Bialy TL, Grant-Kels JM. Skin Cancer. In: Wu G. MD PhD. Screening for Common Malignancies: A Practical Guide, Humana Press, 2001.

Bramlette TB, Lawson DH, Washington CV, Veladar E, Johns B, Freedman S, Abromova L, Chen SC. 2b or Not 2b? Significant differences exist in the decision making process between melanoma patients who accept or decline high-dose adjuvant interferon alfa-2b

• Oral Presentation at the American Society for Dermatologic Surgery Oct. 2006, Palm Desert, CA